Withdrawn 2.0—update on withdrawn drugs with pharmacovigilance data
Nucleic Acids Research · 05.01.2024 · 52 (D1) · D1503-D1507
DOI: 10.1093/nar/gkad1017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 16.11.2023. Verfasst von Kathleen Gallo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Charité - Universitätsmedizin Berlin, Institute of Physiology and GB IT, Science IT, Corporate Member of Freie Universität Berlin, Berlin Institute o…. Hauptthemen laut MEDLINE: Pharmacovigilance, Safety-Based Drug Withdrawals, Databases, Pharmaceutical. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
One challenge in the development of novel drugs is their interaction with potential off-targets, which can cause unintended side-effects, that can lead to the subsequent withdrawal of approved drugs. At the same time, these off-targets may also present a chance for the repositioning of withdrawn drugs for new indications, which are potentially rare or more severe than the original indication and where certain adverse reactions may be avoidable or tolerable. To enable further insights into this topic, we updated our database Withdrawn by adding pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS), as well as mechanism of action and human disease pathway prediction features for drugs that are or were temporarily withdrawn or discontinued in at least one country. As withdrawal data are still spread over dozens of national websites, we are continuously updating our lists of discontinued or withdrawn drugs and related (off-)targets. Furthermore, new systematic entry points for browsing the data, such as an ATC tree, were added, increasing the accessibility of the database in a user-friendly way. Withdrawn 2.0 is publicly available without the need for registration or login at https://bioinformatics.charite.de/withdrawn_3/index.php.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Charité - Universitätsmedizin Berlin, Institute of Physiology and GB IT, Science IT, Corporate Member of Freie Universität Berlin, Berlin Institute of Health, Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
ORCID-Profile: Andrean Goede, Bjoern-Oliver Gohlke, Robert Preissner
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Gallo, K., Goede, A., Eckert, O. A., Gohlke, B. O., & Preissner, R. (2024). Withdrawn 2.0—update on withdrawn drugs with pharmacovigilance data. Nucleic Acids Research, 52(D1), D1503-D1507. https://doi.org/10.1093/nar/gkad1017
Vancouver
Gallo K, Goede A, Eckert OA, Gohlke BO, Preissner R. Withdrawn 2.0—update on withdrawn drugs with pharmacovigilance data. Nucleic Acids Research. 2024;52(D1):D1503-D1507. doi:10.1093/nar/gkad1017
BibTeX
@article{Gallo2024,
author = {Gallo, Kathleen and Goede, Andrean and Eckert, Oliver-Andreas and Gohlke, Bjoern-Oliver and Preissner, Robert},
title = {Withdrawn 2.0—update on withdrawn drugs with pharmacovigilance data},
journal = {Nucleic Acids Research},
year = {2024},
volume = {52},
number = {D1},
pages = {D1503--D1507},
doi = {10.1093/nar/gkad1017}
}
EUVIMED